WuXi Biologics (Cayman) Inc. (2269.HK)
HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
At close: 04:08PM HKT
| Previous close | 89.200 |
| Open | 90.000 |
| Bid | 86.800 x 0 |
| Ask | 86.850 x 0 |
| Day's range | 85.400 - 91.100 |
| 52-week range | 72.100 - 148.000 |
| Volume | |
| Avg. volume | 20,732,272 |
| Market cap | 362.181B |
| Beta (5Y monthly) | 0.99 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline
Exelixis, Inc. (Nasdaq: EXEL) and WuXi Biologics ("WuXi Bio") (2269.HK) today announced the companies have entered into an exclusive license agreement to support the continued expansion of Exelixis’ oncology biologics pipeline. The agreement is the latest in a series of biologics-focused transactions for Exelixis as the company builds out its pipeline behind CABOMETYX® (cabozantinib), its flagship product and global oncology franchise, which received its fourth approval from the U.S. Food and Drug Administration in January.
© 2022 Yahoo. All rights reserved.
